Latest Headlines

  1. Honorhealth Research Institute Patient With Advanced Skin Cancer In Remission For More Than A Year Following Clinical Trial Of Werewolf Therapeutics' Investigational Novel Conditionally Activated IL-2 Pro-Drug WTX-124 5/20/2025

    A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with a new targeted immune-therapy in a clinical trial at HonorHealth Research Institute.

  2. Pfizer Enters Into Exclusive Licensing Agreement With 3SBio 5/19/2025

    Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

  3. Rani Therapeutics Announces Research Agreement With Chugai 5/19/2025

    Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. ("Chugai").

  4. PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform For Novel Phenethylamines 5/15/2025

    PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and subsequent development.

  5. STEERLife Redefines Potent Drug Development With Clean, Green, Continuous Processing 5/15/2025

    STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science.

  6. Viva Biotech Launches The AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery 5/15/2025

    On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive AI-Driven Drug Discovery (AIDD) platform.

  7. Clarivate Enhances OFF-X With Pathway Maps To Accelerate Target Safety Assessments 5/14/2025

    Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution.

  8. AbTherx, Single Cell Technology, And Vaccinex Announce Collaboration To Tackle Challenging Antibody Drug Targets 5/13/2025

    AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced a collaboration with Single Cell Technology and Vaccinex. AbTherx and Single Cell Technology will incorporate Vaccinex's ActivMAb Technology into their respective workflows for complex drug targets.

  9. Comend And Odylia Partner To Advance Rare Disease Drug Development With Innovative Patient-Driven Platform 5/13/2025

    Comend, a software company building solutions for Patient Advocacy Groups (PAGs), and Odylia Therapeutics, a nonprofit drug development organization dedicated to advancing treatments for rare diseases, are excited to announce a strategic partnership aimed at transforming the rare disease research ecosystem.

  10. CytoTronics Expands Pixel Capability With Multi-Modal Cardiac Application For Early Screening Of Drug Candidates In Cardiovascular Research 5/13/2025

    CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched their novel Cardiac application today—the next key offering in its Pixel application portfolio.